

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**NOTICE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of CanSino Biologics Inc. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purpose of, among other matters, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2025 and its publication, and considering the recommendation of payment of final dividend, if any.

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, March 17, 2026

*As of the date of this notice, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.*